Not checkedNot checked for notices yet.
First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
Xiao-Li Wei, Fu-Rong Liu, Ji-Hong Liu and 11 more
Nature Communications · 2022
doi:10.1038/s41467-022-34782-9 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
PIK3CA is a commonly mutated cancer-associated gene, making it an attractive therapeutic target. Here, the authors report the results of a first-in-human phase Ia trial to assess the safety and recommended phase II dose of CYH33, a PI3Kα inhibitor, in patients with advanced solid tumors.
Abstract licence: CC BY-NC-ND
References36
- 1.
- 28.
34 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.